Cancer Family
Benign Connective and Soft Tissue Neoplasm
CI-CAN-00000074Explore in graph →
Non-malignant74 active trials6 evidence items
- NCIt
- C53684
Loading cancer entity…
Cancer Family
CI-CAN-00000074Explore in graph →
Clinical trials
614 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06798363 | Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma | recruiting | Phase 2 / Phase 3 | 32 | West China HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05364008 | FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea(FRIEND) | active not recruiting | Phase 3 | 33 | Yale UniversityOTHER | 1 | Aug 20, 2026 |
| clinicaltrials |
| NCT07656909 | Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP | recruiting | Phase 2 / Phase 3 | 76 | Yi JiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05804045 | Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) | active not recruiting | Phase 3 | 94 | Abbisko Therapeutics Co, LtdINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
| NCT07378098 | to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia | recruiting | Phase 3 | 254 | JW PharmaceuticalINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT06239480 | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations(SELVA) | active not recruiting | Phase 3 | 51 | Palvella Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05059262 | Study of Vimseltinib for Tenosynovial Giant Cell Tumor(MOTION) | active not recruiting | Phase 3 | 123 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Mar 20, 2026 | clinicaltrials |
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | recruiting | Phase 3 | 120 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05862272 | A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | recruiting | Phase 3 | 1,000 | Sumitomo Pharma Switzerland GmbHINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT02923011 | Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas | recruiting | Phase 3 | 56 | Matthew BucknorOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03948789 | Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy | active not recruiting | Phase 3 | 127 | Krankenhaus NordwestOTHER | 1 | Nov 13, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials